FOROPAFANT

Details

Stereochemistry	ACHIRAL
Molecular Formula	C28H40N4S
Molecular Weight	464.709
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)C1=CC(C(C)C)=C(C2=CSC(=N2)N(CCN(C)C)CC3=CC=CN=C3)C(=C1)C(C)C

InChI

InChIKey=VVBFISAUNSXQGZ-UHFFFAOYSA-N

InChI=1S/C28H40N4S/c1-19(2)23-14-24(20(3)4)27(25(15-23)21(5)6)26-18-33-28(30-26)32(13-12-31(7)8)17-22-10-9-11-29-16-22/h9-11,14-16,18-21H,12-13,17H2,1-8H3

HIDE SMILES / InChI

Molecular Formula	C28H40N4S
Molecular Weight	464.709
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://adisinsight.springer.com/drugs/800002078 | https://www.ncbi.nlm.nih.gov/pubmed/10543285 | https://www.ncbi.nlm.nih.gov/pubmed/9834260

Foropafant is a platelet-activating factor (PAF) antagonist which was developed by Sanofi. It was in clinical development for the treatment of asthma, thrombosis and ulcerative colitis. The development of the drug was discontinued due to lack of efficacy.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Platelet-activating factor receptor 3 Target ID: P25105 Gene ID: 5724.0 Gene Symbol: PTAFR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/1656029	Antagonist 2778		57.0 pM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Ulcerative colitis 123 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9834260	Primary	Not Provided 504	Unknown Approved Use Unknown
Acute asthma 2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10543285	Primary	Not Provided 504	Unknown Approved Use Unknown
Thrombosis 22 Sources: http://adisinsight.springer.com/drugs/800002078	Primary	Not Provided 504	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Effect of SR 27417 on the binding of [3H]PAF to rabbit and human platelets and human polymorphonuclear leukocytes.	1993 May	8395255
Role of tachykinins in castor oil diarrhoea in rats.	1997 Jun	9179376
Platelet-leukocyte cross talk in whole blood.	2000 Dec	11116075
Activation of PAF receptor by oxidised LDL in human monocytes stimulates chemokine releases but not urokinase-type plasminogen activator expression.	2004 Jun	15149885

Patents

Sample Use Guides

In Vivo Use Guide

In acute asthma study, foropafant was administered orally at 20 mg dosage

Route of Administration: Oral

In Vitro Use Guide

Foropafant displayed marked in vitro inhibition of PAF-induced oxidative burst in guinea pig macrophages (IC50 = 32 nM). Foropafant potently inhibited PAF-induced aggregation of rabbit and human platelets in vitro (IC50 = 0.10 and 0.50 nM, respectively).

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:38:44 GMT 2023` Edited by `admin` on `Fri Dec 15 16:38:44 GMT 2023`
Record UNII	VWJ2QVH41J
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FOROPAFANT

Official Name

English

3-(((2-(DIMETHYLAMINO)ETHYL)(4-(2,4,6-TRIISOPROPYLPHENYL)-2-THIAZOLYL)AMINO)METHYL)PYRIDINE

Systematic Name

English

foropafant [INN]

Common Name

English

SR-27417

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C1327